Roche Will Be `Thoughtful' on Regeneron Pricing, CEO Says

The video discusses the intense competition from biosimilars and the impact of COVID-19 on business, highlighting a recovery in the third quarter driven by new medicines and COVID-19 tests. It addresses the challenges faced in healthcare visits and chronic disease treatments due to the pandemic. The development of an antibody cocktail with Regeneron is covered, focusing on approval processes and supply issues. The video concludes with a discussion on supply chain challenges and preparations for Brexit.

What was the primary driver for business recovery in the third quarter?

• Expansion into new markets

• Reduction in operational costs

• Newly launched medicines and COVID-19 tests

• Increased competition from biosimilars

What percentage of pre-COVID levels have patient visits returned to?

• 90%

• 80%

• 70%

• 100%

Which chronic disease was mentioned as having a good recovery in treatment rates?

• Multiple sclerosis

• Hypertension

• Diabetes

• Asthma

What is the current status of the antibody cocktail developed with Regeneron?

• It is available for free worldwide

• Emergency use authorization has been filed in the US

• It is in the early stages of development

• It has been approved in Europe

What is the main focus regarding the antibody cocktail's market introduction?

• Exclusive distribution in the US

• Immediate global distribution

• Conducting confirmatory clinical trials and ramping up supply

• Pricing discussions with governments

What operational issue has been resolved in the UK?

• Lack of diagnostic equipment

• Shipping delays related to COVID-19 testing

• Shortage of medical staff

• Brexit-related trade barriers

How has the company prepared for a potential no-deal Brexit?

• By halting all UK operations

• By increasing prices of goods

• By developing contingency plans for continuous supply

• By relocating headquarters to the EU